This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Concert Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

38.9%

Wachstumsrate der Gewinne

43.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum28.4%
Wachstumsrate der Einnahmen54.9%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert06 Mar 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

Jan 22
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

CinCor Pharma hits 52-week high on data for antihypertensive agent

Aug 08

Concert Pharmaceuticals: A Balanced Risk/Reward

Jun 15

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Jun 04
We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug

Jun 03

Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Jan 11
Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Aug 27
Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

May 25
We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Concert Pharma EPS beats by $0.02

May 04

Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Feb 27
Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia

Feb 01

Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Jan 23
Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

Dec 19
How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Nov 23
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Concert Pharma EPS beats by $0.15

Nov 05

Concert Pharma launches late-stage study of CTP-543 in hair loss disorder

Nov 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CNCE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202596-69N/A-862
12/31/202429-129N/A-1402
12/31/202318-137N/A-783
12/31/20220-122N/AN/A3
9/30/202232-127-110-110N/A
6/30/202233-125-103-102N/A
3/31/202233-95-67-67N/A
12/31/202133-80-55-55N/A
9/30/20211-66-45-45N/A
6/30/20212-59-47-47N/A
3/31/20218-77-72-72N/A
12/31/20208-75-69-69N/A
9/30/20208-73-68-68N/A
6/30/20206-71-64-63N/A
3/31/20200-77-66-65N/A
12/31/20191-78-49-49N/A
9/30/20191-79-50-49N/A
6/30/20191-79-47-45N/A
3/31/20191-73-40-37N/A
12/31/201811-56-51-48N/A
9/30/201811-41-41-39N/A
6/30/201811104104106N/A
3/31/201811104104105N/A
12/31/2017095103104N/A
9/30/20170899899N/A
6/30/20170-50-46-45N/A
3/31/20170-50-45-44N/A
12/31/20160-51-46-45N/A
9/30/201610-38-33-33N/A
6/30/201612-35N/A-30N/A
3/31/20161519N/A20N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CNCE is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: CNCE is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: CNCE is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: CNCE's revenue (54.9% per year) is forecast to grow faster than the US market (7% per year).

Hohe Wachstumseinnahmen: CNCE's revenue (54.9% per year) is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken